Clinical trials
Completed Phase 2/3 trials in Iran
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 8 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 5 |
| 2012 | 8 |
| 2013 | 7 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 64 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Isfahan University of Medical Sciences | 14 |
| Tehran University of Medical Sciences | 13 |
| Shiraz University of Medical Sciences | 11 |
| Shahid Beheshti University of Medical Sciences | 5 |
| National Nutrition and Food Technology Institute | 4 |
| Royan Institute | 4 |
| Islamic Azad University, Sanandaj | 2 |
| Mazandaran University of Medical Sciences | 2 |
| Ahvaz Jundishapur University of Medical Sciences | 1 |
| Amirhossein Farahmand | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myocardial Infarction | 3 |
| Angina, Stable | 2 |
| Coronary Artery Disease | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Diabetic Nephropathies | 2 |
| Gastrointestinal Diseases | 2 |
| Infertility | 2 |
| Influenza, Human | 2 |
| Irritable Bowel Syndrome | 2 |
| Mucositis | 2 |
Trials
Showing 1 to 25 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.